A new study reveals that dasatinib and quercetin (D+Q) cause demyelination in mice, raising safety concerns as over 30 clinical trials test the combo for age-related diseases. A study in Nature Aging ...
Recent studies show senescent cells can both help and hinder wound repair. Understanding this balance offers new therapeutic strategies for chronic wounds and aging. Senescent cells are not just ̵...
Senolytics like dasatinib and quercetin are transforming dermatology from cosmetic fixes to true biological rejuvenation, with recent trials showing improved skin elasticity and potential for treating...
A comparative study reveals that dasatinib-quercetin reduces senescence and fibrosis in intervertebral disc degeneration, while navitoclax shows no benefit, highlighting DQ’s potential for affor...
Dermatology is shifting from surface-level cosmetics to biology-driven interventions targeting aging hallmarks, with senolytics, epigenetic reprogramming, and biomimetic peptides leading the charge. D...
Large animals like whales and elephants have evolved superior DNA repair and cancer suppression mechanisms, offering insights for human aging and disease prevention. New studies reveal how massive mam...
Phase 1 trial of RLS-1496 demonstrates safety with no severe adverse events and significant reduction in inflammatory markers, highlighting its potential as a senolytic therapy for skin conditions lik...
Recent breakthroughs in senolytic and senomorphic therapies, including polyunsaturated lipids inducing ferroptosis, are advancing clinical trials for age-related diseases, with a focus on safety and b...
Exploring recent advances in senolytic and senomorphic therapies, including dasatinib-quercetin and immune-based approaches, to combat age-related diseases like Alzheimer’s and sarcopenia. New t...
Recent studies link IGFBP7 from senescent cells to reduced exercise benefits in older adults, with senolytic therapies offering new avenues for enhanced fitness and healthy aging interventions. IGFBP7...